greeksoup/ stock research

Resmed (RMD) Q3 FY2026 earnings: revenue $1.4 billion, up 10.8% on the year

Resmed Inc. (RMD) reported revenue of $1.4 billion for Q3 FY2026, the quarter ended 31 March 2026, up 10.8% on the same quarter a year earlier. Net income was $399 million, up 9.2% on the year, and diluted earnings per share $2.74. The figures are the company's own, from the 10-Q it filed with the SEC on 1 May 2026.

Revenue
$1.4 billion
+10.8% on the year · +0.6% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
34.9%
33.0% a year earlier
Q4 FY2024Q3 FY2026
Net income
$399 million
+9.2% on the year · +1.6% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$2.74
+10.5% on the year · +2.2% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

  • Revenue rose 11% to $1.43 billion: The company reported revenue of $1,431.4 million, up 11% from $1,291.7 million, or 8% on a constant currency basis, driven by demand for sleep devices, masks and accessories.
  • Operating income up 17%, EPS up 10%: GAAP income from operations rose 17% to $499.8 million. GAAP diluted EPS was $2.74, up 10%. Non-GAAP diluted EPS was $2.86, up 21%, against $2.37 a year earlier.
  • Masks and other grew faster than devices: Devices revenue was $735.7 million, up 9% (6% constant currency). Masks and other revenue was $524.8 million, up 15% (12% constant currency).
Read the earnings call summary

Income statement (profit and loss)

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Revenue1,4311,4231,292+0.6%+10.8%
Cost of revenue540544525-0.7%+2.9%
Gross profit891879766+1.4%+16.3%
Gross margin62.2%61.8%59.3%
Research and development94.391.083.9+3.6%+12.3%
Selling, general and administrative286278245+2.6%+16.5%
Operating income500492426+1.7%+17.3%
Operating margin34.9%34.6%33.0%
Pre-tax income502496418+1.2%+20.3%
Income tax10410452.7+0.0%+96.7%
Effective tax rate20.6%20.9%12.6%
Net income399393365+1.6%+9.2%
Net margin27.9%27.6%28.3%
Diluted EPS$2.74$2.68$2.48+2.2%+10.5%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Operating cash flow554340579+63.1%-4.2%
Capital expenditure33.728.520.8+17.9%+61.8%
Free cash flow520311558+67.2%-6.7%
Free cash flow margin36.4%21.9%43.2%
Cash from investing-58.0-50.9-31.8
Cash from financing-255-258-144
Depreciation and amortisation59.049.943.7+18.2%+35.0%
Share-based compensation26.828.924.1-7.4%+11.1%
Buybacks17517575.0-0.0%+133.3%
Dividends paid87.287.677.7-0.4%+12.3%
Dividend per share$0.60$0.60$0.530.0%+13.2%
Diluted shares, weighted146m146m147m-0.4%-1.0%
Shares outstanding at period end145m146m147m-0.4%-1.1%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Shareholders' equity6,4926,3215,546+2.7%+17.1%
Debt664664673+0.0%-1.3%
Operating lease liabilities150154138-2.8%+8.6%
Other liabilities1,4781,3651,210+8.3%+22.2%
Total liabilities and equity8,7848,5037,567+3.3%+16.1%
Fixed assets567564535+0.5%+5.9%
Goodwill3,0433,0442,849-0.0%+6.8%
Intangible assets425430430-1.2%-1.1%
Cash and equivalents1,6611,417933+17.2%+78.0%
Receivables999986908+1.3%+10.0%
Inventory912922863-1.1%+5.7%
Other assets1,1781,1401,049+3.3%+12.2%
Total assets8,7848,5037,567+3.3%+16.1%

Questions

What was Resmed's revenue in Q3 FY2026?

Resmed (RMD) reported revenue of $1.4 billion for Q3 FY2026, the quarter ended 31 March 2026, up 10.8% on the same quarter a year earlier.

How much did Resmed earn in Q3 FY2026?

Net income for Q3 FY2026 was $399 million, up 9.2% on the year, and diluted earnings per share $2.74.

When did Resmed report Q3 FY2026 results?

Resmed filed its 10-Q for the quarter ended 31 March 2026 with the SEC on 1 May 2026.

Quarterly results, the last 20 quarters

Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026 †Q2 FY2026Q3 FY2026Q4 FY2026 *Q1 FY2027
Revenue8958649159501,0341,1171,1221,1021,1631,1971,2231,2251,2821,2921,3481,3361,4231,4311,4641,415
Cost of revenue391373392409454499505502516504508507531525528518544540602544
Gross profit504491523541580618617600647693716717751766820818879891861871
Gross margin56%57%57%57%56%55%55%54%56%58%58%59%59%59%61%61%62%62%59%62%
R&D62.566.864.363.269.976.478.175.773.977.180.979.581.483.986.489.591.094.3106103
SG&A185182195194212228240223222230242239242245265259278286296315
Operating income249234255276280301275289275375381387417426455447492500449453
Operating margin28%27%28%29%27%27%25%26%24%31%31%32%33%33%34%33%35%35%31%32%
Interest expense5.95.5n/an/an/an/an/an/an/an/an/an/an/an/an/a7.1n/an/an/a4.8
Pre-tax income237226238262274289277272259375358383418418458447496502474539
Tax rate15%21%18%20%18%20%17%19%20%20%18%19%18%13%17%22%21%21%19%22%
Net income202179195210225232230219209300292311345365380349393399383418
Net margin23%21%21%22%22%21%20%20%18%25%24%25%27%28%28%26%28%28%26%30%
Diluted EPS$1.37$1.22$1.32$1.43$1.53$1.58$1.56$1.49$1.42$2.04$1.98$2.11$2.34$2.48$2.58$2.37$2.68$2.74$2.64$2.92
Operating cash flow22011779.544.7129283237286273402440326309579539457340554455422
Capital expenditure30.448.428.629.127.428.834.430.023.421.224.917.820.620.830.643.028.533.751.148.7
Free cash flow18969.050.815.6101254203256249381415308288558508414311520404374
Buybacksn/an/an/an/an/a0.0n/a0.050.050.050.050.075.075.0100150175175200936
Dividends paid61.261.461.564.464.564.664.770.670.770.570.677.977.777.777.687.887.687.287.195.0
Shares outstanding146m146m146m146m147m147m147m147m147m147m147m147m147m147m146m146m146m145m144m141m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 31 March 2026, filed 1 May 2026: the filing.